Australia's recent election has highlighted the slow vote-counting process, prompting political leaders, including Prime Minister Malcolm Turnbull and Opposition leader Bill Shorten, to advocate for electronic voting. Despite the potential for faster results, experts like Vanessa Teague from the University of Melbourne caution against security vulnerabilities. The debate reflects a rare consensus among Australia's divided parliament, though concerns remain about the loss of traditional election day customs and the integrity of electronic systems.

The U.S. dollar remained strong against major currencies, supported by higher Treasury yields following a significant increase in U.S. private-sector jobs in February. The ADP National Employment Report indicated a larger-than-expected job growth, which has led to a high likelihood of a Federal Reserve rate hike. The dollar index was slightly up, and the 10-year Treasury yield reached its highest since December. The euro was near a one-week low, with the market anticipating the European Central Bank's policy meeting. Analysts suggest the ECB may adopt a hawkish tone due to rising economic growth and inflation. Upcoming elections in the Netherlands and France, with the rise of populist sentiment, are also influencing market volatility.

The dollar retreated after reaching one-month highs due to upbeat U.S. economic data, as Treasury yields came off their peaks. U.S. inflation and retail sales data had initially boosted expectations of an early Federal Reserve rate hike. However, some analysts noted that the data might not be as strong as it appears, with industrial output and home builder sentiment showing unexpected declines. The dollar index and its value against the yen both fell, while the euro and Australian dollar saw slight recoveries. Fed Chair Janet Yellen hinted at more rate hikes but provided no specific timeline.

The dollar steadied after hitting a five-week low against the yen and other currencies, following a news conference by U.S. President-elect Donald Trump that left investors disappointed. Chinese trade data, expected to show a growing trade surplus, is in focus. The dollar index fell to its lowest level since December 8, while the yen and euro saw gains. Analysts suggest the dollar may regain momentum with clearer details on Trump's fiscal policies. U.S. Treasuries yields are expected to rise due to increasing inflation expectations, bolstered by recent U.S. jobs data showing significant wage growth.

The dollar slipped from its 14-year high against a basket of currencies as investors took profits ahead of holidays and upcoming U.S. economic data. The Federal Reserve's signal for more frequent rate hikes in 2017 limited the dollar's decline. The euro rebounded slightly but faces pressure due to the troubled Monte dei Paschi di Siena bank in Italy, which is likely to require a state rescue. The Swedish crown saw significant gains after Sweden's central bank extended its bond purchase program.

The article provides a comprehensive update on the progress of various coronavirus vaccine candidates. It highlights the involvement of several companies and institutions in developing genetic, viral vector, and whole-virus vaccines. Key collaborations include those between Fosun Pharma and Pfizer, Osaka University and Takara Bio, and the University of Oxford. Notable developments include the publication of trial results in reputable journals and the Chinese government's approval of a vaccine for military use. The article emphasizes the anticipated timelines for vaccine availability and production capacities.

Samumed, a leading health tech unicorn, is gaining attention for its innovative approach to reversing aging through the regulation of adult stem cells, particularly via the Wnt pathway. The company is developing treatments for knee arthritis, hair loss, Alzheimer's disease, and oncology. A notable collaboration with L’Oreal aims to develop anti-wrinkle skincare applications. CEO Osman Kibar emphasizes the company's mission to restore youth and peak health.

Eli Lilly has begun human trials for LY-CoV555, a potential COVID-19 antibody treatment designed to neutralize the virus by blocking its entry into human cells. The White House, according to the New York Times, has selected five coronavirus vaccine candidates, with an official announcement expected soon. There are currently ten vaccine candidates in clinical trials, with efforts focused on using existing drugs, discovering new drugs, and developing vaccines.

Moderna's CEO, Stephane Bancel, discusses the interim Phase 1 results of their COVID-19 vaccine, highlighting its safety and efficacy in eliciting neutralizing antibodies. The company plans to advance to Phase 2 with 600 participants and aims to start Phase 3 in July. Moderna has partnered with Lonza to significantly increase manufacturing capacity, targeting up to 1 billion doses per year. Bancel addresses stock sales by executives, emphasizing pre-planned transactions. The interview underscores the importance of manufacturing partnerships and the potential for mRNA vaccines.

Moderna's Phase 1 trial data for its COVID-19 vaccine indicates it is generally safe and elicits an immune response, with neutralizing antibodies observed in participants. However, the long-term efficacy, appropriate dosage, and large-scale manufacturing capabilities remain uncertain. The company plans to proceed with Phase 2 and Phase 3 trials, aiming for potential vaccine availability by late 2020 or early 2021. The World Health Organization notes that there are currently 10 vaccine candidates in human trials.